ClinicalTrials.gg
RecruitingNCT06852638Updated May 12, 2026

CD70-targeted immunoPET Imaging of Malignant Cancers

A Phase 2 interventional study of [18F]F-RESCA-RCCB6 and [18F]F-RESCA-R8B4 in Renal Cancer, Renal Clear Cell Carcinoma and Lymphoma, sponsored by RenJi Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by RenJi Hospital · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Kidney Neoplasms with a site in China — 47 open to participants now, 51 under way, 3 of them phase 3. Kidney Neoplasms · China.

Planned enrollment
11th of 50
300 · median 123
Started
2024
with 9 others
Phase 2
16 of 68
12 open now
Primary completion
2026-12
later than 18 of 50 live
Registered
44th of 68
by date
Lead sponsor
6 of 68
RenJi Hospital

Among the 68 studies in Kidney Neoplasms with a site in China, this one is the 11th largest by planned enrollment of the 50 interventional ones that give a count, is one of 10 that started in 2024, is one of 16 in phase 2, reaches primary completion later than 18 of the 50 other live ones, and was the 44th registered.

Kidney Neoplasms

969 studies on the registry are indexed under Kidney Neoplasms; 208 are open to participants now.

Browse Kidney Neoplasms studies →

Open to participants now

47 of the 68 studies in Kidney Neoplasms with a site in China are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 171 Kidney Neoplasms studies recruiting now, 131 (77%) set no upper age limit and 15 (9%) stop at 75 or younger; 20 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Kidney Neoplasms with a site in China, or all of them as a file.
02

Study summary

This study aims to determine the value of cluster of differentiation (CD70)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging for diagnosing human malignancies, including renal cell carcinoma (particularly clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma (NPC), among others.

Read the detailed description

Histologically confirmed malignant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)) or patients with suspected malignant cancers (renal cancer (especially clear cell renal cell carcinoma), lymphoma, or nasopharyngeal carcinoma (NPC)) indicated by conventional diagnostic imaging will be included. Patients will also be included for routine follow-up, surveillance, and evaluation of treatment efficacy following the initial CD70-targeted immunoPET/CT imaging.

Enrolled patients will undergo whole-body immunoPET/CT scans 1-2 hours after tracer injection (0.01-0.1 mCi/kg). Uptake of imaging tracers in tumors and normal organs/tissues will be scored both visually and quantitatively.

Tumor uptake will be quantified using the maximum standard uptake value (SUVmax). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy will be calculated to assess diagnostic efficacy. The correlation between lesion uptake and CD70 expression levels, as determined by immunohistochemical staining, will be further analyzed. The primary exploratory endpoint will be the imaging feasibility of the tracers and their preliminary diagnostic value compared with conventional imaging approaches such as 18F-FDG PET/CT, CT/MRI. The secondary endpoint is the impact of CD70-targeted immunoPET/CT imaging on clinical decision-making.

03

Conditions studied

  • Renal Cancer
  • Renal Clear Cell Carcinoma
  • Lymphoma
  • Lymphoma, Large B-Cell, Diffuse
  • Follicular Lymphoma
  • Mantle Cell Lymphoma
  • Nasopharyngeal Carcinoma

Keywords

  • The cluster of differentiation (CD70)
  • ImmunoPET
  • Renal Cancer
  • Lymphoma
  • Nasopharyngeal Carcinoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18-80 year-old and of either sex;
  • confirmed diagnosis of renal cancer (especially ccRCC)/lymphoma/NPC or suspected renal cancer/lymphoma/NPC by diagnostic imaging;
  • Capable of giving signed , including compliance with the requirements and restrictions in the informed consent form (ICF) and this protocol.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy;
  • Severe hepatic and renal insufficiency;
  • Allergic to single-domain antibody radiopharmaceuticals.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    CD70-targeted immunoPET imaging

    Enrolled patients will undergo a CD70-targeted immunoPET/CT scanning.

    Drug: [18F]F-RESCA-RCCB6 · Drug: [18F]F-RESCA-R8B4 · Drug: [68Ga]Ga-NOTA-R8B4 · Drug: [18F]F-RESCA-RD06 · Drug: [68Ga]Ga-NOTA-RD06

Interventions

  • Drug[18F]F-RESCA-RCCB6

    Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]RCCB6. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]RCCB6 injection.

    Also known as: [18F]RCCB6

  • Drug[18F]F-RESCA-R8B4

    Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]R8B4 injection.

    Also known as: [18F]R8B4

  • DrugGallium-68Studies of Gallium-68Gallium-68 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]R8B4. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]R8B4 injection.

    Also known as: [68Ga]R8B4

  • Drug[18F]F-RESCA-RD06

    Enrolled patients will receive 0.01-0.1 mCi/kg of \[18F\]F-RESCA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[18F\]F-RESCA-RD06 injection.

  • DrugGallium-68Studies of Gallium-68Gallium-68 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Enrolled patients will receive 0.01-0.1 mCi/kg of \[68Ga\]Ga-NOTA-RD06. ImmunoPET/CT imaging will be acquired 1-2 hours after \[68Ga\]Ga-NOTA-RD06 injection.

06

What researchers measure

Primary outcomes

  1. The uptake patterns of CD70-targeted tracers across different tumors

    Because the expression level of CD70 varies across tumors, including renal cell carcinoma (especially clear cell renal cell carcinoma), nasopharyngeal carcinoma, and lymphoma, due to different regulatory pathways, this variation will lead to differential uptake of CD70 tracers in these tumors. Therefore, the primary goal of the prospective study is to determine the uptake and distribution patterns of CD70-targeted tracers in patients with renal cell carcinoma (particularly clear cell), nasopharyngeal carcinoma, or lymphoma. To achieve this, imaging tracer uptake in tumors and normal organs/tissues will be scored both visually and quantitatively. Uptake will be correlated with CD70 expression determined by immunohistochemical staining.

    Time frame: One month after the injection of the tracers

  2. The diagnostic value of CD70-targeted immunoPET/CT across different tumors

    The primary outcome of the prospective study is to determine the diagnostic value of CD70-targeted immunoPET/CT in human malignancies, especially renal cell carcinoma (with a focus on clear cell renal cell carcinoma), lymphoma, and nasopharyngeal carcinoma. To achieve this, tumor uptake will be quantified using the maximum standard uptake value (SUVmax). sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy will be calculated to assess diagnostic efficacy. The correlation between lesion uptake and CD70 expression levels, as determined by immunohistochemical staining, will be further analyzed. The comparative diagnostic value of CD70-targeted immunoPET/CT, relative to traditional imaging approaches such as 18F-FDG PET/CT and CT/MRI, will be assessed in selected patients.

    Time frame: One month from the injection of the tracers

Secondary outcomes

  1. The impact of CD70-targeted immunoPET/CT on clinical decision-making

    The secondary outcome of the study is to determine the impact of CD70-targeted immunoPET/CT on clinical decision-making, especially for patients with clear cell renal cell carcinoma.

    Time frame: 3-6 months after the injection of the tracers

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Dec 2026, 24 months after the start.

Of 64 non-industry phase 2 interventional studies under Kidney Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 112. This study's planned 24 months is below that.

Counting every sponsor, half of 74 studies reached it within 67 months; a quarter within 36 and three quarters within 112.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2025
First posted
Feb 28, 2025
StartActual
Dec 23, 2024
Primary completionEst.
Dec 23, 2026
CompletionEst.
Dec 23, 2026
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06852638
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Feb 28, 2025
Start date
Dec 23, 2024
Primary completion
Dec 23, 2026 (estimated)
Completion
Dec 23, 2026 (estimated)
Last update
May 12, 2026

Study contacts

Weijun Wei, Ph.D. & M.D.
Contact
wwei@shsmu.edu.cn
15000083153
Jianjun Liu, Ph.D. & M.D.
study chair · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University
Weijun Wei, Ph.D. & M.D.
principal investigator · Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gallium-68

Start the discussion